Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology August 1, 2024 Roger S McIntyre, Istvan Bitter, Jozefien Buyze et al. 30 citations
In the ESCAPE-TRD trial, esketamine nasal spray caused treatment-emergent adverse events more often than quetiapine extended release (91.9% versus 78.0%), but these events were typically mild or moderate and transient: 92.0% resolved the same day, and only 4.2% of patients discontinued esketamine due to adverse events compared with 11.0% for quetiapine. The median proportion of days with adverse events was lower with esketamine (11.9% versus 21.3%). Along with greater efficacy, esketamine's tolerability profile supports its use for treatment-resistant depression.